Tarsus Pharmaceuticals, Inc.
TARS
Rang în acțiuni
#4560
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Preț acțiune
$71.65
Capitalizare de piață
$3.35B
Schimbare (1 zi)
0.88%
Schimbare (1 an)
1.17%
Țară
US
Tranzacționează Tarsus Pharmaceuticals, Inc. (TARS)
Categorie
Healthcare
Venituri pentru Tarsus Pharmaceuticals, Inc. (TARS)
Venituri în Jun 2026 TTM: $606.33M
Conform celor mai recente rapoarte financiare ale Tarsus Pharmaceuticals, Inc., venitul actual al companiei (TTM) este $606.33M. În anul 2023, compania a avut un venit de $17.45M o scădere comparativ cu venitul din anul 2022, care a fost de $25.82M. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Tarsus Pharmaceuticals, Inc. din 2018 până în 2026
Venituri la sfârșitul fiecărui an
| An | Venituri | Schimbă |
|---|---|---|
| 2026 (TTM) | $606.33M | 231.41% |
| 2024 | $182.95M | 948.62% |
| 2023 | $17.45M | -32.42% |
| 2022 | $25.82M | -54.73% |
| 2021 | $57.03M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Venituri pentru companii similare sau concurente
| Companie | Venituri | Diferență de venituri | Țara |
|---|---|---|---|
| $12.62B | 1,982.08% |
US
|
|
| $2.23B | 267.46% |
US
|
|
| $15.74B | 2,496.66% |
AU
|
|
| $6.02B | 893.07% |
NL
|
|
| - | - |
CH
|
